DiBiase Mary has filed 17 insider transactions across 1 company since February 2023.
Most recent transaction: a grant/award of 650000 shares of X4 Pharmaceuticals, Inc ($XFOR) on February 12, 2025.
Activity breakdown: 0 open-market purchases and 12 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 12, 2025 | X4 Pharmaceuticals, Inc | $XFOR | DiBiase Mary | Chief Operating Officer | A | Common Stock | 650000 | $0.00 | 1,140,980.0000 | 201,062,211 | 132.39% | 0.32% |
| Jan. 23, 2025 | X4 Pharmaceuticals, Inc | $XFOR | DiBiase Mary | Chief Operating Officer | A | Common Stock | 61178 | $0.00 | 513,238.0000 | 201,062,211 | 13.53% | 0.03% |
| Jan. 24, 2025 | X4 Pharmaceuticals, Inc | $XFOR | DiBiase Mary | Chief Operating Officer | S | Common Stock | 22258 | $0.45 | 490,980.0000 | 201,062,211 | 4.34% | 0.01% |
| Oct. 4, 2024 | X4 Pharmaceuticals, Inc | $XFOR | DiBiase Mary | Chief Operating Officer | A | Common Stock | 230645 | $0.00 | 519,755.0000 | 6,695,509 | 79.78% | 3.44% |
| Oct. 7, 2024 | X4 Pharmaceuticals, Inc | $XFOR | DiBiase Mary | Chief Operating Officer | S | Common Stock | 67695 | $0.57 | 452,060.0000 | 6,695,509 | 13.02% | 1.01% |
| Sept. 9, 2024 | X4 Pharmaceuticals, Inc | $XFOR | DiBiase Mary | Chief Operating Officer | S | Common Stock | 2642 | $0.66 | 289,110.0000 | 177,812,480 | 0.91% | 0.00% |
| March 11, 2024 | X4 Pharmaceuticals, Inc | $XFOR | DiBiase Mary | Chief Operating Officer | S | Common Stock | 15409 | $0.88 | 291,752.0000 | 177,812,480 | 5.02% | 0.01% |
| Feb. 13, 2024 | X4 Pharmaceuticals, Inc | $XFOR | DiBiase Mary | Chief Operating Officer | A | Stock Appreciation Right | 428248 | $0.00 | 428,248.0000 | 177,812,480 | 9999.99% | 0.24% |
| Feb. 12, 2024 | X4 Pharmaceuticals, Inc | $XFOR | DiBiase Mary | Chief Operating Officer | S | Common Stock | 3683 | $1.01 | 307,161.0000 | 177,812,480 | 1.18% | 0.00% |
| Nov. 1, 2023 | X4 Pharmaceuticals, Inc | $XFOR | DiBiase Mary | Chief Operating Officer | S | Common Stock | 67695 | $0.73 | 310,844.0000 | 63,525,845 | 17.88% | 0.11% |
| Oct. 31, 2023 | X4 Pharmaceuticals, Inc | $XFOR | DiBiase Mary | Chief Operating Officer | A | Common Stock | 230645 | $0.00 | 378,539.0000 | 63,525,845 | 155.95% | 0.36% |
| Sept. 8, 2023 | X4 Pharmaceuticals, Inc | $XFOR | DiBiase Mary | Chief Operating Officer | S | Common Stock | 2642 | $1.25 | 147,894.0000 | 63,525,845 | 1.76% | 0.00% |
| June 30, 2023 | X4 Pharmaceuticals, Inc | $XFOR | DiBiase Mary | Chief Operating Officer | S | Common Stock | 464 | $1.89 | 150,536.0000 | 63,525,845 | 0.31% | 0.00% |
| June 23, 2023 | X4 Pharmaceuticals, Inc | $XFOR | DiBiase Mary | Chief Operating Officer | S | Common Stock | 857 | $1.93 | 151,000.0000 | 63,525,845 | 0.56% | 0.00% |
| June 15, 2023 | X4 Pharmaceuticals, Inc | $XFOR | DiBiase Mary | Chief Operating Officer | S | Common Stock | 857 | $2.23 | 151,857.0000 | 63,525,845 | 0.56% | 0.00% |
| March 10, 2023 | X4 Pharmaceuticals, Inc | $XFOR | DiBiase Mary | Chief Operating Officer | S | Common Stock | 18192 | $0.84 | 152,714.0000 | 63,525,845 | 10.64% | 0.03% |
| Feb. 13, 2023 | X4 Pharmaceuticals, Inc | $XFOR | DiBiase Mary | Chief Operating Officer | S | Common Stock | 4348 | $0.93 | 170,906.0000 | 63,525,845 | 2.48% | 0.01% |